Application of a person-centered prescription model improves pharmacotherapeutic indicators and reduces costs associated with pharmacological treatment in hospitalized older patients at the end of life

Alexander Ferro-Uriguen, Idoia Beobide-Telleria, Javier Gil-Goikouria, Petra Teresa Peña-Labour, Andrea Díaz-Vila, Arlovia Teresa Herasme-Grullón, Enrique Echevarría-Orella, Jesús Seco-Calvo, Alexander Ferro-Uriguen, Idoia Beobide-Telleria, Javier Gil-Goikouria, Petra Teresa Peña-Labour, Andrea Díaz-Vila, Arlovia Teresa Herasme-Grullón, Enrique Echevarría-Orella, Jesús Seco-Calvo

Abstract

Objective: This study sought to investigate whether applying an adapted person-centered prescription (PCP) model reduces the total regular medications in older people admitted in a subacute hospital at the end of life (EOL), improving pharmacotherapeutic indicators and reducing the expense associated with pharmacological treatment.

Design: Randomized controlled trial. The trial was registered with ClinicalTrials.gov (NCT05454644).

Setting: A subacute hospital in Basque Country, Spain.

Subjects: Adults ≥65 years (n = 114) who were admitted to a geriatric convalescence unit and required palliative care.

Intervention: The adapted PCP model consisted of a systematic four-step process conducted by geriatricians and clinical pharmacists. Relative to the original model, this adapted model entails a protocol for the tools and assessments to be conducted on people identified as being at the EOL.

Measurements: After applying the adapted PCP model, the mean change in the number of regular drugs, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria, drug burden index (DBI), drug-drug interactions, medication regimen complexity index (MRCI) and 28-days medication cost of chronic prescriptions between admission and discharge was analyzed. All patients were followed for 3 months after hospital discharge to measure the intervention's effectiveness over time on pharmacotherapeutic variables and the cost of chronic medical prescriptions.

Results: The number of regular prescribed medications at baseline was 9.0 ± 3.2 in the intervention group and 8.2 ± 3.5 in the control group. The mean change in the number of regular prescriptions at discharge was -1.74 in the intervention group and -0.07 in the control group (mean difference = 1.67 ± 0.57; p = 0.007). Applying a PCP model reduced all measured criteria compared with pre-admission (p < 0.05). At discharge, the mean change in 28-days medication cost was significantly lower in the intervention group compared with the control group (-34.91€ vs. -0.36€; p < 0.004).

Conclusion: Applying a PCP model improves pharmacotherapeutic indicators and reduces the costs associated with pharmacological treatment in hospitalized geriatric patients at the EOL, continuing for 3 months after hospital discharge. Future studies must investigate continuity in the transition between hospital care and primary care so that these new care models are offered transversally and not in isolation.

Keywords: deprescribing; end of life (EOL); older people; palliative medicine; person-centered prescription.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Ferro-Uriguen, Beobide-Telleria, Gil-Goikouria, Peña-Labour, Díaz-Vila, Herasme-Grullón, Echevarría-Orella and Seco-Calvo.

Figures

Figure 1
Figure 1
Person-centered prescription model at the end of life.
Figure 2
Figure 2
Recruitment and participation.

References

    1. Etkind SN, Bone AE, Gomes B, Lovell N, Evans CJ, Higginson IJ, et al. . How many people will need palliative care in 2040? Past trends, future projections and implications for services. BMC Med. (2017) 15:1–10. 10.1186/s12916-017-0860-2
    1. Finucane AM, Bone AE, Etkind S, Carr D, Meade R, Munoz-Arroyo R, et al. . How many people will need palliative care in Scotland by 2040? A mixed-method study of projected palliative care need and recommendations for service delivery. BMJ Open. (2021) 11:e041317. 10.1136/bmjopen-2020-041317
    1. Amblàs-Novellas J, Espaulella J, Rexach L, Fontecha B, Inzitari M, Blay C, et al. . Frailty, severity, progression and shared decision-making : a pragmatic framework for the challenge of clinical complexity at the end of life. Eur Geriatr Med. (2015) 6:189–94. 10.1016/j.eurger.2015.01.002
    1. Hernández-Rodríguez MÁ, Sempere-Verdú E, Vicens-Caldentey C, González-Rubio F, Miguel-García F, Palop-Larrea V, et al. . Evolution of polypharmacy in a spanish population (2005–2015): a database study. Pharmacoepidemiol Drug Saf. (2020) 29:433–43. 10.1002/pds.4956
    1. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. (2018) 17:1185–96. 10.1080/14740338.2018.1546841
    1. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. (2014) 13:57–65. 10.1517/14740338.2013.827660
    1. Cruz-Jentoft AJ, Boland B, Rexach L. Drug therapy optimization at the end of life. Drugs Aging. (2012) 29:511–21. 10.2165/11631740-000000000-00000
    1. O'mahony D, O'connor MN. Pharmacotherapy at the end-of-life. Age Aging. (2011) 40:419–22. 10.1093/aging/afr059
    1. Morin L, Vetrano DL, Rizzuto D, Calderón-Larrañaga A, Fastbom J, Johnell K. Choosing wisely? Measuring the burden of medications in older adults near the end of life: nationwide, longitudinal cohort study. Am J Med. (2017) 130:927–36.e9. 10.1016/j.amjmed.2017.02.028
    1. Morin L, Wastesson JW, Laroche ML, Fastbom J, Johnell K. How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study. Palliat Med. (2019) 33:1080–90. 10.1177/0269216319854013
    1. Gómez-Batiste X, Martínez-Muñoz M, Blay C, Amblàs J, Vila L, Costa X, et al. . Utility of the NECPAL CCOMS-ICO tool and the surprise question as screening tools for early palliative care and to predict mortality in patients with advanced chronic conditions: a cohort study. Palliat Med. (2017) 31:754–63. 10.1177/0269216316676647
    1. Care B the AGSEP on P-C . Person-centered care: a definition and essential elements. J Am Geriatr Soc. (2016) 64:15–8. 10.1111/jgs.13866
    1. Heaton J, Britten N, Krska J, Reeve J. Person-centered medicines optimisation policy in England: an agenda for research on polypharmacy. Prim Heal Care Res Dev. (2017) 18:24–34. 10.1017/S1463423616000207
    1. Rovira C, Modamio P, Pascual J, Armengol J, Ayala C, Gallego J, et al. . Person-centered care provided by a multidisciplinary primary care team to improve therapeutic adequacy in polymedicated elderly patients (PCMR): randomized controlled trial protocol. BMJ Open. (2022) 12:e051238. 10.1136/bmjopen-2021-051238
    1. Espaulella-Panicot J, Molist-Brunet N, Sevilla-Sánchez D, González-Bueno J, Amblàs-Novellas J, Solà-Bonada N, et al. . Patient-centered prescription model to improve adequate prescription and therapeutic adherence in patients with multiple disorders. Rev Esp Geriatr Gerontol. (2017) 52:278–81. 10.1016/j.regg.2017.03.002
    1. Stuck AE, Siu AL, Wieland GD, Rubenstein LZ, Adams J. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. (1993) 342:1032–6. 10.1016/0140-6736(93)92884-V
    1. Thompson W, Lundby C, Graabaek T, Nielsen DS, Ryg J, Søndergaard J, et al. . Tools for deprescribing in frail older persons and those with limited life expectancy: a systematic review. J Am Geriatr Soc. (2019) 67:172–80. 10.1111/jgs.15616
    1. Shrestha S, Poudel A, Steadman K, Nissen L. Outcomes of deprescribing interventions in older patients with life-limiting illness and limited life expectancy: a systematic review. Br J Clin Pharmacol. (2020) 86:1931–45. 10.1111/bcp.14113
    1. Reuben DB, Tinetti ME. Goal-oriented patient care-an alternative health outcomes paradigm. N Engl J Med. (2012) 366:777–9. 10.1056/NEJMp1113631
    1. Tinetti ME, Fried T. The end of the disease era. Am J Med. (2004) 116:179–85. 10.1016/j.amjmed.2003.09.031
    1. Gómez-Batiste X. Identification of people with chronic advanced diseases and need of palliative care in sociosanitary services: elaboration of the NECPAL CCOMS-ICO tool. Med Clin (Barc). (2013) 140:241–5. 10.1016/j.medcli.2012.06.027
    1. Vicente J, González G. Evaluation of the reliability and validity of a scale of social evaluation of the elderly. Aten Primaria. (1999) 23:434–40.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie R. A new method of classifying prognostic in longitudinal studies: development and validation. J Chronic Dis. (1987) 40:373–83. 10.1016/0021-9681(87)90171-8
    1. Amblàs-Novellas J, Martori JC, Molist Brunet N, Oller R, Gómez-Batiste X, Espaulella Panicot J. Frail-VIG index: design and evaluation of a new frailty index based on the comprehensive geriatric assessment. Rev Esp Geriatr Gerontol. (2016) 52:119–27. 10.1016/j.regg.2016.09.003
    1. Reisberg B, Ferris S, De Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. (1982) 139:1136–9. 10.1176/ajp.139.9.1136
    1. Carvajal Valcárcel A, Martinez García M, Centeno Cortés C. The Spanish version of the edmonton symptom assessment system-revised (ESAS-r): first psychometric analysis involving patients with advanced cancer. J Pain Symptom Manag. (2013) 20:143–9. 10.1016/j.jpainsymman.2012.01.014
    1. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. . A method for assesing drug therapy appropriateness. J Clin Epidmiol. (1992) 45:1045–51. 10.1016/0895-4356(92)90144-C
    1. Lavan AH, Gallagher P, Parsons C, O'Mahony D. STOPPFrail (screening tool of older persons prescriptions in frail adults with limited life expectancy): consensus validation. Age Aging. (2017) 46:600–7. 10.1093/aging/afx005
    1. By the American Geriatrics Society 2015 Beers Criteria Update Panel Expert . American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. (2015) 63:2227–46. 10.1111/jgs.13702
    1. George J, Phun YT, Bailey MJ, Kong DCM, Stewart K. Development validation of the medication regimen complexity index. Ann Pharmacother. (2004) 38:1369–76. 10.1345/aph.1D479
    1. . BOT Plus 2. Base de Datos de Medicamentos. Available online at: (accessed December 30, 2021).
    1. Hilmer SN, Mager DE, Simonsick EM, Ying Cao MB, Ling SM, Windham BG, et al. . A drug burden index to define the functional burden of medications in older people. Am Geriatr Soc. (2007) 167:781–7. 10.1001/archinte.167.8.781
    1. Nordin Olsson I, Runnamo R, Engfeldt P. Medication quality and quality of life in the elderly, a cohort study. Health Qual Life Outcomes. (2011) 9:95. 10.1186/1477-7525-9-95
    1. Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of potentially inappropriate prescribing on adverse drug events, health related quality of life and emergency hospital attendance in older people attending general practice: a prospective cohort study. J Gerontol A Biol Sci Med Sci. (2017) 72:271–7. 10.1093/gerona/glw140
    1. Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in frail older people: a randomized controlled trial. PLoS ONE. (2016) 11:1–21. 10.1371/journal.pone.0149984
    1. Ahmad A, Mast MR, Nijpels G, Elders PJM, Dekker JM, Hugtenburg JG. Identification of drug-related problems of elderly patients discharged from hospital. Patient Prefer Adherence. (2014) 8:155–65. 10.2147/PPA.S48357
    1. Vasilevskis EE, Shah AS, Hollingsworth EK, Shotwell MS, Mixon AS, Bell SP, et al. . patient-centered deprescribing intervention for hospitalized older patients with polypharmacy: rationale and design of the Shed-MEDS randomized controlled trial. BMC Health Serv Res. (2019) 19:1–13. 10.1186/s12913-019-3995-3
    1. Palmer K, Marengoni A, Forjaz MJ, Jureviciene E, Laatikainen T, Mammarella F, et al. . Multimorbidity care model: recommendations from the consensus meeting of the joint action on chronic diseases and promoting healthy aging across the life cycle (JA-CHRODIS). Health Policy. (2018) 122:4–11. 10.1016/j.healthpol.2017.09.006
    1. Sabaté E,. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization (2003). Available online at: (accessed May 23, 2022).
    1. González-Bueno J, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Molist-Brunet N, Codina-Jané C, Espaulella-Panicot J. Improving medication adherence and effective prescribing through a patient-centered prescription model in patients with multimorbidity. Eur J Clin Pharmacol. (2022) 78:127–37. 10.1007/s00228-021-03207-9
    1. Molist-Brunet N, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Barneto-Soto M, González-Bueno J, Espaulella-Panicot J. Improving individualized prescription in patients with multimorbidity through medication review. BMC Geriatr. (2022) 22:417. 10.1186/s12877-022-03107-2
    1. Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Khatun M, et al. . The development and evaluation of an oncological palliative care deprescribing guideline: the ‘OncPal deprescribing guideline'. Support Care Cancer. (2015) 23:71–8. 10.1007/s00520-014-2322-0
    1. Mcneill R, Hanger HC, Chieng J, Chin P. Polypharmacy in palliative care: two deprescribing tools compared with a clinical review. J Palliat Med. (2021) 24:661–7. 10.1089/jpm.2020.0225
    1. Steinman MA, Miao Y, Boscardin WJ, Komaiko KDR, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. (2014) 29:1379. 10.1007/s11606-014-2924-8
    1. Curtin D, Gallagher P, O'Mahony D. Deprescribing in older people approaching end-of-life: development and validation of STOPPFrail version 2. Age Aging. (2021) 50:465–71. 10.1093/aging/afaa159
    1. Pedrós C, Formiga F, Corbella X, Arnau JM. Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. Eur J Clin Pharmacol. (2016) 72:219–26. 10.1007/s00228-015-1974-0
    1. Marengoni A, Pasina L, Concoreggi C, Martini G, Brognoli F, Nobili A, et al. . Understanding adverse drug reactions in older adults through drug-drug interactions. Eur J Intern Med. (2014) 25:843–6. 10.1016/j.ejim.2014.10.001
    1. Swart F, Bianchi G, Lenzi J, Lommi M, Maestri L, Raschi E, et al. . Risk of hospitalization from drug-drug interactions in the elderly: real-world evidence in a large administrative database. Aging. (2020) 12:19711–39. 10.18632/aging.104018
    1. Byrne CJ, Walsh C, Cahir C, Ryan C, Williams DJ, Bennett K. Anticholinergic and sedative drug burden in community-dwelling older people: a national database study. BMJ Open. (2018) 8:1–8. 10.1136/bmjopen-2018-022500
    1. Kreher M. Symptom control at the end of life. Med Clin North Am. (2016) 100:1111–22. 10.1016/j.mcna.2016.04.020
    1. Hochman MJ, Kamal AH, Wolf SP, Samsa GP, Currow DC, Abernethy AP, et al. . Anticholinergic drug burden in non-cancer vs cancer patients near the end of life. J Pain Symptom Manage. (2016) 52:737–43.e3. 10.1016/j.jpainsymman.2016.03.020
    1. Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med. (2009) 23:257–65. 10.1177/0269216309102528

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner